A number of research firms have changed their ratings and price targets for Werewolf Therapeutics (NASDAQ: HOWL): 6/4/2024 – Werewolf Therapeutics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock. 6/3/2024 – Werewolf Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. […]
Frazier Life Sciences Management L.P. lifted its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 7.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,381,090 shares of the company’s stock after purchasing an additional 500,000 shares during […]
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) COO Susanna Gatti High sold 80,000 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $30.24, for a total value of $2,419,200.00. Following the completion of the transaction, the chief operating officer now owns 154,062 […]
Avidity Partners Management LP cut its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 37.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 827,010 shares of the company’s stock after selling 495,990 shares during the period. Avidity Partners Management […]
Shares of Omega Therapeutics, Inc. (NASDAQ:OMGA – Get Free Report) shot up 14.5% during trading on Wednesday . The stock traded as high as $2.22 and last traded at $2.13. 882,095 shares changed hands during mid-day trading, a decline of 38% from the average session volume of 1,430,338 shares. The stock had previously closed at […]